Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839396 | 0.91 | PDE4B (0.55) | CNR2CNR1RAB9APDE4BPDE4D | |
| SCHEMBL5747125 | 0.91 | TAS1R3 (0.50) | CNR2CNR1RAB9APDE4BPDE4D | |
| SCHEMBL5753712 | 0.90 | RAB9A (0.47) | CNR2CNR1RAB9APDE4BPDE4D | |
| SCHEMBL5753703 | 0.90 | RAB9A (0.47) | CNR2CNR1RAB9APDE4BPDE4D | |
| SCHEMBL5841178 | 0.90 | AURKA (0.47) | CNR2CNR1RAB9APDE4BPDE4D | |
| SCHEMBL5841455 | 0.90 | RAB9A (0.49) | CNR2CNR1RAB9APDE4BPDE4D | |
| SCHEMBL8319888 | 0.89 | RAB9A (0.47) | CNR2CNR1RAB9APDE4BPDE4D | |
| SCHEMBL5750322 | 0.89 | RAB9A (0.59) | CNR2CNR1RAB9AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL5751698 | 0.89 | RAB9A (0.46) | CNR2CNR1RAB9APDE4BPDE4D | |
| Hydrochloric Acid SCHEMBL5751702 | 0.89 | RAB9A (0.46) | CNR2CNR1RAB9APDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | claimed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | CNR2 88/4885CNR1 29/4885RAB9A 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.